Ticagrelor + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Community Acquired Pneumonia, Severe
Conditions
Community Acquired Pneumonia, Severe
Trial Timeline
Aug 1, 2014 → Dec 1, 2015
NCT ID
NCT01998399About Ticagrelor + Placebo
Ticagrelor + Placebo is a phase 2 stage product being developed by AstraZeneca for Community Acquired Pneumonia, Severe. The current trial status is terminated. This product is registered under clinical trial identifier NCT01998399. Target conditions include Community Acquired Pneumonia, Severe.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03615924 | Phase 3 | Terminated |
| NCT03354429 | Phase 3 | Completed |
| NCT02482298 | Phase 2 | Completed |
| NCT02352402 | Phase 3 | UNKNOWN |
| NCT02110303 | Phase 2/3 | Completed |
| NCT02335099 | Phase 1/2 | Completed |
| NCT01998399 | Phase 2 | Terminated |
| NCT02070653 | Phase 2 | Completed |
| NCT01347580 | Approved | Completed |
Competing Products
17 competing products in Community Acquired Pneumonia, Severe